Impaired glucose tolerance, diabetes, and cardiovascular disease.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Oliver Schnell, Eberhard Standl

Abstract

To analyze the association among impaired glucose tolerance (IGT), diabetes, and cardiovascular disease (CVD). We review current studies that have addressed the foregoing relationship and summarize the results of diagnostic and therapeutic interventions. A major cause of the reduction in life expectancy in patients with diabetes is CVD and cardiovascular complications. Both prediabetes and diabetes predispose to cardiovascular alterations. IGT and even the upper normal values of nondiabetic glucose levels are associated with an increased cardiovascular risk. The risk of heart disease can be increased as early as 15 years before the diagnosis of diabetes. Patients with chronic or acute CVD and no previous diagnosis of diabetes frequently present with either IGT or diabetes. Thus, such patients should undergo screening for diabetes with an oral glucose tolerance test. In acute coronary syndromes, lowering of glucose levels to the near-normal range by administration of insulin is highly beneficial. Early, rigorous interventions to improve metabolic control will yield better cardiovascular outcomes in patients with dysglycemia. Aggressive preventive and treatment strategies, which can include multiple interventions, are needed to m...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Jan 11, 2001·Diabetologia·E Standl, O Schnell
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Jun 28, 2002·Lancet·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trail Research Group
Feb 11, 2003·Critical Care Medicine·Greet Van den BerghePeter Lauwers
Jul 24, 2003·JAMA : the Journal of the American Medical Association·Jean-Louis ChiassonUNKNOWN STOP-NIDDM Trial Research Group
Feb 27, 2004·Diabetic Medicine : a Journal of the British Diabetic Association·W OtterO Schnell
Dec 4, 2004·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·C ThiloO Schnell

❮ Previous
Next ❯

Citations

Aug 2, 2013·Asian Pacific Journal of Tropical Biomedicine·Onakpa Michael Monday, Asuzu Isaac Uzoma
May 16, 2008·Journal of Human Hypertension·A K GuptaF Halberg
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Giuseppe Derosa, Sibilla At Salvadeo
Apr 10, 2008·Journal of Clinical Biochemistry and Nutrition·Moussa NdongKazuharu Suzuki
Nov 26, 2015·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Diego Gomez-ArbelaezPatricio Lopez-Jaramillo
Dec 15, 2007·Metabolism: Clinical and Experimental·Sofiya AlhassanChristopher D Gardner
Jan 30, 2009·Basic & Clinical Pharmacology & Toxicology·Rannveig Linda ThorisdottirJens Sandahl Christiansen
Oct 9, 2014·Endocrine·Martin BuysschaertJaqueline Lonier
Oct 2, 2007·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Gabriele PerrielloUNKNOWN Italian Pioglitazone Study Group
Feb 22, 2007·Clinical Chemistry and Laboratory Medicine : CCLM·Ulrich JuliusJens Pietzsch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.